Literature DB >> 16529884

Ciprofloxacin permeability and its active secretion through rat small intestine in vitro.

Simon Zakelj1, Katja Sturm, Albin Kristl.   

Abstract

The biopharmaceutical aspect of the fluoroquinolones-metal cations interaction, which reduces antibacterial agents bioavailability and the mechanism of the fluoroquinolone intestinal efflux are still poorly understood. The purpose of this work was to gain further insights into these two issues by measuring the permeability of ciprofloxacin through the rat small intestine in side-by-side diffusion chambers using different incubation media and transport inhibitors. The permeability of ciprofloxacin from the mucosal to the serosal side was low. It was not influenced by the different concentrations of Ca(2+) and Mg(2+) in the donor solution. The active efflux of ciprofloxacin was the highest in the region of the rat small intestine excised proximal to the ileo-caecal junction or when the pH value of the incubation saline was slightly acidic. Thus ciprofloxacin appears to be transported in its cationic or in its zwitterionic form. The efflux was not inhibited by verapamil, benzbromarone or quinidine, which were added to the mucosal side of the intestinal tissue. It was however inhibited by quinidine added to the serosal side. The active secretion is therefore most probably a consequence of the organic cation transporter 1 activity at the basolateral membrane of enterocytes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16529884     DOI: 10.1016/j.ijpharm.2006.02.004

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2).

Authors:  I S Haslam; J A Wright; D A O'Reilly; D J Sherlock; T Coleman; N L Simmons
Journal:  Drug Metab Dispos       Date:  2011-09-19       Impact factor: 3.922

2.  Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters.

Authors:  J A Schrickx; J Fink-Gremmels
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

3.  In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients.

Authors:  Katja Berginc; Simon Žakelj; Albin Kristl
Journal:  Eur J Nutr       Date:  2010-02-07       Impact factor: 5.614

4.  A ciprofloxacin extended release tablet based on swellable drug polyelectrolyte matrices.

Authors:  José M Bermúdez; Alvaro F Jimenez-Kairuz; Maria E Olivera; Daniel A Allemandi; Ruben H Manzo
Journal:  AAPS PharmSciTech       Date:  2008-08-07       Impact factor: 3.246

5.  Screening and In Vitro Evaluation of Mucoadhesive Thermoresponsive System Containing Methylene Blue for Local Photodynamic Therapy of Colorectal Cancer.

Authors:  Fernanda Belincanta Borghi-Pangoni; Mariana Volpato Junqueira; Sabrina Barbosa de Souza Ferreira; Larissa Lachi Silva; Bruno Ribeiro Rabello; Wilker Caetano; Andrea Diniz; Marcos Luciano Bruschi
Journal:  Pharm Res       Date:  2015-11-09       Impact factor: 4.200

6.  The impact of therapeutic-dose induced intestinal enrofloxacin concentrations in healthy pigs on fecal Escherichia coli populations.

Authors:  Joren De Smet; Filip Boyen; Siska Croubels; Geertrui Rasschaert; Freddy Haesebrouck; Robin Temmerman; Sofie Rutjens; Patrick De Backer; Mathias Devreese
Journal:  BMC Vet Res       Date:  2020-10-08       Impact factor: 2.741

7.  Effects of berberine and hwangryunhaedok-tang on oral bioavailability and pharmacokinetics of ciprofloxacin in rats.

Authors:  Youn-Hwan Hwang; Won-Kyung Cho; Doorye Jang; Jeong-Ho Ha; Kiyoun Jung; Hyo-In Yun; Jin Yeul Ma
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-24       Impact factor: 2.629

8.  Pharmacokinetics of gallic acid and protocatechuic acid in humans after dosing with Relinqing (RLQ) and the potential for RLQ-perpetrated drug-drug interactions on organic anion transporter (OAT) 1/3.

Authors:  Ziqiang Li; Xi Du; Yanfen Li; Ruihua Wang; Changxiao Liu; Yanguang Cao; Weidang Wu; Jinxia Sun; Baohe Wang; Yuhong Huang
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.